Matching-adjusted indirect treatment comparison of tarlatamab versus comparator therapies in England in patients with extensive-stage small cell lung cancer who have received two or more prior lines of therapy
Takundwa, R. Suri, G. Dirnberger, F. Verhoek, A. Vinand, E. Wang, J. Puntis, S. Pundole, X. Blackhall, F.
Takundwa, R.
Suri, G.
Dirnberger, F.
Verhoek, A.
Vinand, E.
Wang, J.
Puntis, S.
Pundole, X.
Blackhall, F.
Abstract
INTRODUCTION: The non-comparative phase 2 DeLLphi-301 trial found that tarlatamab, a bispecific T cell engager immunotherapy, can provide sustained objective response rates and improved survival outcomes for patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). In the absence of direct head-to-head evidence, an indirect treatment comparison was conducted to estimate the efficacy of tarlatamab relative to comparator therapies in England. METHODS: The outcomes of patients in the DeLLphi-301 trial were compared against those of a comparator therapies cohort identified through linkage of population-level real-world databases in England. The study population consisted of patients with relapsed ES-SCLC who received two or more prior lines of therapy and who met key eligibility criteria from the DeLLphi-301 trial. Outcomes of interest included overall survival (OS) and progression-free survival (PFS). An unanchored matching-adjusted indirect comparison (MAIC) was used to estimate the efficacy of tarlatamab relative to available comparator therapies, adjusting for key baseline characteristics to match the patient cohort from DeLLphi-301 with the comparator therapies cohort. A weighted Cox proportional hazards model with robust variance estimation was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for both OS and PFS. RESULTS: The analyses included 97 patients enrolled in the DeLLphi-301 trial and 540 patients receiving available treatment options in England. After matching, tarlatamab was associated with improved OS (HR 0.24; 95% CI 0.14, 0.43) and PFS (HR 0.18; 95% CI 0.11, 0.31) relative to the comparator therapies. Findings were similar in sensitivity analyses performed by changing the variables for adjustment. CONCLUSION: Tarlatamab provides a clinically meaningful survival benefit compared to currently available treatments in England. These findings support the use of tarlatamab as an effective treatment option for patients with previously treated ES-SCLC.
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Takundwa R, Suri G, Dirnberger F, Verhoek A, Vinand E, Wang J, et al. Matching-adjusted indirect treatment comparison of tarlatamab versus comparator therapies in England in patients with extensive-stage small cell lung cancer who have received two or more prior lines of therapy. Advances in therapy. 2025 Oct 8. PubMed PMID: 41060525. Epub 2025/10/08. eng.